Examining the mechanisms that govern astrocytic Tau regulation in primary tauopathies with glial cytopathology suggests that distinguishing endogenous synthesis from neuronal uptake is essential to define glial-mediated pathology and recognize astrocytic Tau as a relevant contributor to neurodegenerative disease progression.
Abstract
The Tau protein is traditionally recognized for stabilizing axonal microtubules in neurons. However, emerging evidence indicates that astrocytes also show basal expression of the microtubule-associated protein Tau (MAPT) gene, with potential implications for central nervous system (CNS) homeostasis. Under physiological conditions, astrocytes support functions essential to CNS integrity, including metabolic support, neurotransmitter uptake, blood–brain barrier maintenance, and immune surveillance, all of which may be influenced by endogenous Tau expression. This review examines the current literature on the mechanisms that govern astrocytic Tau regulation, mainly in primary tauopathies with glial cytopathology. Available data indicate that Tau accumulation in these glial cells arises from endogenous synthesis, uptake from neighboring neurons, or a combination of these pathways, while failed extracellular clearance may favor this process by increasing Tau availability in the extracellular space. Once internalized, Tau can be processed, degraded through proteolytic and autophagic-lysosomal pathways, or re-released into the extracellular space, potentially facilitating its propagation; insufficient degradation, in contrast, promotes reactive astrogliosis and disrupts vital processes such as metabolic support and neurotransmitter handling. Taken together, this evidence suggests that distinguishing endogenous synthesis from neuronal uptake is essential to define glial-mediated pathology and recognize astrocytic Tau as a relevant contributor to neurodegenerative disease progression.
Using isogenic human induced pluripotent stem cell-derived microglia carrying the pathogenic MAPT IVS10+16 mutation, tau is identified as a regulator of microglial lysosomal function and degradative capacity is identified as a modifiable component of the microglial response to tau pathology.
Kylie J. Schache, Rui Zhang, Audrey Street et al.· bioRxiv· 0 citations
GFAP is an efficient biomarker in CSF, plasma, and saliva, which is associated with amyloid pathology, cognitive impairment, and AD, and can be used to extract significant information about AD mechanisms and find opportunities to identify diagnosis, prognosis and therapy.
Riddhi Upadhyay, T. Srinivasan, R. Umapriya et al.· International review of neur...· 0 citations
The axon initial segment (AIS) is a specialized neuronal compartment integrating action potential initiation with selective control of axonal trafficking. The microtubule-associated protein tau is a central regulator of cytoskeletal organization and transport, yet how distinct tau isoforms contribute to AIS development...